Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Wellington Management Group LLP Boston, MA7.9MShares$245 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$220 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$184 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$173 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$162 Million4.29% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.81MShares$118 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.68MShares$114 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY3.33MShares$103 Million0.16% of portfolio
-
State Street Corp Boston, MA2.5MShares$77.7 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.02MShares$62.6 Million0.02% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,061
-5.47%
|
$253,708
$28.26 P/Share
|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,061
+9.82%
|
$190,281
$21.1 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-11.88%
|
$350,000
$35.19 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.62%
|
$0
$0.62 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
108,366
-8.06%
|
$3,359,346
$31.99 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,366
+7.35%
|
$2,275,686
$21.1 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,716
-6.63%
|
$1,622,912
$32.15 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,716
+13.23%
|
$855,036
$21.09 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,485
-17.27%
|
$495,520
$32.62 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,485
+14.73%
|
$325,185
$21.1 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,515
-5.74%
|
$144,480
$32.53 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,515
+5.43%
|
$94,815
$21.1 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
63,539
-4.75%
|
$1,969,709
$31.83 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
63,539
+8.67%
|
$1,334,319
$21.1 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
3,103
-0.51%
|
$96,193
$31.12 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,103
+0.51%
|
$65,163
$21.1 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
24,992
-3.96%
|
$774,752
$31.14 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+3.81%
|
$524,832
$21.1 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14,825
-8.26%
|
$444,750
$30.72 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,825
+14.13%
|
$0
$0.62 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 245K shares |
|---|---|
| Exercise of conversion of derivative security | 934K shares |
| Open market or private purchase | 200K shares |
| Open market or private sale | 874K shares |
|---|